UGT1A1 sequence variants associated with risk of adult hyperbilirubinemia: A quantitative analysis

Gene

Volumn 552, Issue 1, 2014, Pages 32-38

  Chen, Zhiwei ^a   Su, Dazhi ^a   Ai, Luoyan ^a   Jiang, Xiaoke ^a   Wu, Changwei ^a   Xu, Qingqing ^a   Wang, Xiaohan ^a   Fan, Zhuping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Case and control study; Gene mutation; Hyperbilirubinemia; Single nucleotide polymorphism; UDP glucuronosyltransferase 1

Indexed keywords

BILIRUBIN; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME;

ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE DOSAGE; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GILBERT DISEASE; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROTEIN TERTIARY STRUCTURE; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; BLOOD; CASE CONTROL STUDY; EVALUATION STUDY; GENE FREQUENCY; GENETICS; GENOTYPE;

ADULT; BILIRUBIN; CASE-CONTROL STUDIES; EVALUATION STUDIES AS TOPIC; EXONS; FEMALE; GENE FREQUENCY; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; HYPERBILIRUBINEMIA; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84908009381     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.09.009     Document Type: Article

References (36)

1. Mackenzie P.I., Owens I.S., Burchell B., et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997, 7:255-269.
2. Strassburg C.P., Manns M.P., Tukey R.H. Expression of the UDP-glucuronosyltransferase 1A locus in humancolon. Identification and characterization of the novel extrahepatic UGT1A8. J. Biol. Chem. 1998, 273:8719-8726.
3. Gil J., Sasiadek M.M. Gilbert syndrome: the UGT1A1*28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism. Biomark. Med 2012, 6:223-230.
4. Tukey R.H., Strassburg C.P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 2000, 40:581-616.
5. Fretzayas A., Moustaki M., Liapi O., et al. Gilbert syndrome. Eur. J. Pediatr. 2012, 171:11-15.
6. Raijmakers M.T., Jansen P.L., Steegers E.A., et al. Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J. Hepatol. 2000, 33:348-351.
7. Hirschfield G.M., Alexander G.J. Gilbert's syndrome: an overview for clinical biochemists. Ann. Clin. Biochem. 2006, 43:340-343.
8. Kadakol A., Ghosh S.S., Sappal B.S., et al. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum. Mutat. 2000, 16:297-306.
9. Sticova E., Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J. Gastroenterol. 2013, 19:6398-6407.
10. Sissung T.M., Baum C.E., Kirkland C.T., et al. Pharmacogenetics of membrane transporters: an update on current approaches. Mol. Biotechnol. 2010, 44:152-167.
11. Sadee W., Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum. Mol. Genet. 2005, 14(Spec No. 2):R207-14.
12. Strassburg C.P. Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 2008, 9:703-715.
13. Palomaki G.E., Bradley L.A., Douglas M.P., et al. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet. Med. 2009, 11:21-34.
14. Mathijssen R.H., van Alphen R.J., Verweij J., et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 2001, 7:2182-2194.
15. Innocenti F., Vokes E.E., Ratain M.J. Irinogenetics: what is the right star?. J. Clin. Oncol. 2006, 24:2221-2224.
16. Liu J.Y., Qu K., Sferruzza A.D., et al. Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals. Anticancer Drugs 2007, 18:693-696.
17. Ando Y., Saka H., Ando M., et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000, 60:6921-6926.
18. Girard H., Thibaudeau J., Court M.H., et al. UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology 2005, 42:448-457.
19. Kataoka R., Kimata A., Yamamoto K., et al. Association of UGT1A1 Gly71Arg with urine urobilinogen. Nagoya J. Med. Sci. 2011, 73:33-40.
20. Ando Y., Chida M., Nakayama K., et al. The UGT1A1* 28 allele is relatively rare in a Japanese population. Pharmacogenet. Genomics 1998, 8:357-360.
21. Huang C.S., Huang M.J., Lin M.S., et al. Genetic factors related to unconjugated hyperbilirubinemia amongst adults. Pharmacogenet. Genomics 2005, 15:43-50.
22. Guo D., Pang L.F., Zhou H.H. Progress in the study of UDP-glucuronosyltransferase gene polymorphism. Sheng Li Ke Xue Jin Zhan 2010, 41:107-111.
23. Strassburg C.P. Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg?. Drug Metab. Rev. 2010, 42:168-181.
24. Balram C., Sabapathy K., Fei G., et al. Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 2002, 12:81-83.
25. Sugatani J., Yamakawa K., Yoshinari K., et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem. Biophys. Res. Commun. 2002, 292:492-497.
26. Rodrigues C., Vieira E., Santos R., et al. Impact of UGT1A1 gene variants on total bilirubin levels in Gilbert syndrome patients and in healthy subjects. Blood Cells Mol. Dis. 2012, 48:166-172.
27. Alkharfy K.M., Alghamdi A.M., Bagulb K.M., et al. Distribution of selected gene polymorphisms of UGT1A1 in a Saudi population. Arch. Med. Sci. 2013, 9:731-738.
28. Costa E., Vieira E., Dos Santos R. The polymorphism c.-3279T>G in the phenobarbital-responsive enhancer module of the bilirubin UDP-glucuronosyltransferase gene is associated with Gilbert syndrome. Clin. Chem. 2005, 51:2204-2206.
29. Bosma P.J., Chowdhury J.R., Bakker C., et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 1995, 333:1171-1175.
30. Maruo Y., Wada S., Yamamoto K., et al. A case of anorexia nervosa with hyperbilirubinaemia in a patient homozygous for a mutation in the bilirubin UDP-glucuronosyltransferase gene. Eur. J. Pediatr. 1999, 158:547-549.
31. Maruo Y., D'Addario C., Mori A., et al. Two linked polymorphic mutations (A(TA)7TAA and T-3279G) of UGT1A1 as the principal cause of Gilbert syndrome. Hum. Genet. 2004, 115:525-526.
32. Teng H.C., Huang M.J., Tang K.S., et al. Combined UGT1A1 and UGT1A7 variant alleles are associated with increased risk of Gilbert's syndrome in Taiwanese adults. Clin. Genet. 2007, 72:321-328.
33. Johnson A.D., Kavousi M., Smith A.V., et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum. Mol. Genet. 2009, 18:2700-2710.
34. Matsui K., Maruo Y., Sato H., et al. Combined effect of regulatory polymorphisms on transcription of UGT1A1 as a cause of Gilbert syndrome. BMC Gastroenterol. 2010, 10:57.
35. Ferraris A., D'Amato G., Nobili V., et al. Combined test for UGT1A1-3279T→G and A(TA)nTAA polymorphisms best predicts Gilbert's syndrome in Italian pediatric patients. Genet. Test. 2006, 10:121-125.
36. Canu G., Minucci A., Zuppi C., et al. Gilbert and Crigler Najjar syndromes: an update of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene mutation database. Blood Cells Mol. Dis. 2013, 50:273-280.